Story
Grand Pharmaceutical's FAP-Targeting Cancer Diagnostic Granted FDA Fast Track Designation

Grand Pharmaceutical Group Ltd. (00512.HK) announced its investigational radiopharmaceutical, GPN01530-2, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA). The drug is the first diagnostic agent targeting Fibroblast Activation Protein (FAP) for solid tumors to be granted this status, according to the company's announcement.
FDA Designation and Development
The FDA's Fast Track program is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. Grand Pharma stated that the designation signals regulatory recognition of the drug's potential and could shorten its development and approval timeline.
The company previously received FDA clearance to begin Phase I/II clinical trials for GPN01530-2 as a diagnostic for solid tumors. The Fast Track status marks a significant milestone in its U.S. clinical development program.
The FAP Target and Market Potential
GPN01530-2 is a radiopharmaceutical diagnostic (RDC) that targets Fibroblast Activation Protein (FAP). FAP is highly expressed in over 90% of epithelial tumors but has low expression in healthy tissue, making it a promising and specific target for cancer imaging and therapy.
AdAccording to Grand Pharma, its drug uses an optimized ligand structure to improve tumor uptake and pharmacokinetic properties. The company reported that early human studies showed superior clinical image contrast and more accurate detection of positive lesions compared to the current standard imaging agent, 18F-FDG.
The potential market for an alternative to 18F-FDG is estimated to be over $5 billion, the source material noted. Citing data from Frost & Sullivan, it also highlighted that the global oncology drug market is projected to reach $702.7 billion by 2035, underscoring the significant commercial opportunity for innovative diagnostics.
Strategic Implications for Grand Pharma
This regulatory milestone positions Grand Pharma as a key competitor in the rapidly growing field of nuclear medicine, particularly in the race to develop FAP-targeted agents. The company is pursuing a "dual filing" strategy to seek regulatory approval in both the United States and China.
Grand Pharma has been building an integrated radiopharmaceutical business, with a pipeline of 16 products in development and global facilities for research and manufacturing. The company aims to leverage this infrastructure to advance GPN01530-2 and other internally developed products for the global oncology market.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.